Table 5.
Individual checkpoint blockade.
| Target | Agent | Antibody type | Developmental stage and clinical trial references† |
|---|---|---|---|
| CTLA4 | Ipilimumab (MDX-010) | Human lgG1 mAb | US FDA approved for melanoma Phase I/II, II clinical trials in melanoma 1. NCT01585194† 2. NCT01689974† Phase III clinical trials in melanoma 1. NCT00094653§ 2. NCT01515189¶ |
| Tremelimumab (CP-675, 206) | Human lgG2 mAb | Phase II clinical trials 1. NCT00471887¶ – melanoma 2. NCT01649024¶ – mesothelioma |
|
| PD1 | Nivolumab (BMS-936558 or MDX1106) |
Human lgG4 mAb | Phase 1 clinical trials 1. NCT01176461† – melanoma Phase I/II clinical trial 1. NCT01928394† – solid tumors Phase II clinical trial 1. NCT01354431¶ – renal cell cancer Phase III clinical trials 1. NCT01844505† – untreated melanoma |
| Lambrolizumab (MK-3475) |
Human lgG4 mAb | Phase I clinical trial 1. NCT01295827† – solid tumors Phase II clinical trial 1. NCT02085070† – melanoma and NSCLC Phase III clinical trial 1. NCT01866319¶ – melanoma |
|
| Pidilizumab(CT-011) | Human lgG1 mAb | Phase I/II clinical trial 1. NCT01952769† – glioblastoma multiforme Phase II clinical trials 1. NCT01435369§ – melanoma 2. NCT01313416† – pancreatic cancer |
|
| AMP-224 | PDL2 Ig fusion protein | Phase I clinical trial 1. NCT01352884¶ – cancers |
|
| PDL1 | MDX-1105 (BMS-936559) |
Human lgG4 mAb | Phase 1 clinical trial 1. NCT00729664¶ – solid tumors |
| MPDL3280A | Engineered lgG1 (no ADCC) |
Phase 1 clinical trial 1. NCT01375842† – Solid tumors 2. NCT02013219‡ – NSCLC Phase II clinical trials for NSCLC 1. NCT02031458† 2. NCT01903993† |
|
| LAG-3 | BMS-986016 | Human IgG mAb | Phase 1 clinical trials 1. NCT0206176† – hematologic neoplasms |
| IMP321 | Soluble LAG-3 | Phase I clinical trial 1. NCT00351949§ – renal cell cancer Phase I/II clinical trial 1. NCT01308294† – melanoma |
|
Representative trials, not meant to be exhaustive list of all trials.
Clinical trial status obtained March 2014 from the ClinicalTrials.gov website maintained by the NIH.
†
Recruiting.
‡
Not yet recruiting.
§
Completed.
¶
Active, not recruiting.
ADCC: Antibody-dependent cell-mediated cytotoxicity; mAb: Monoclonal antibody; NSCLC: Non-small-cell lung cancer.